Dutch Biotech Merus Raises €21.7 Million ($30.7 Million)

Published: Jan 29, 2010

Bookmark and Share

peHUB -- Merus, a biopharmaceutical company located in Utrecht, The Netherlands, announced today that it has closed a €21.7 million ($30.7 million) Series B financing round led by new investors the Novartis Option Fund, Pfizer Inc. (New York), Bay City Capital (San Francisco), and LSP (Life Sciences Partners; Amsterdam). Merus’ seed investor Aglaia Oncology Fund (Bilthoven) also participated in this financing.

Back to news